Bivalent COVID-19 Shot Effective for Preventing Thromboembolic Events
By Elana Gotkine HealthDay Reporter
THURSDAY, Jan. 11, 2024 -- A bivalent mRNA COVID-19 vaccine after receipt of an original monovalent COVID-19 vaccine is effective for preventing COVID-19-related thromboembolic events, according to research published in the Jan. 11 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Amanda B. Payne, Ph.D., from the CDC in Atlanta, and colleagues estimated the incremental benefit of receipt of a bivalent mRNA COVID-19 vaccine after receipt of an original monovalent COVID-19 vaccine. Two retrospective cohort studies were conducted among Medicare fee-for-service enrollees during Sept. 4, 2022, to March 4, 2023, to estimate the vaccine effectiveness (VE) of a bivalent mRNA COVID-19 dose for preventing thromboembolic events versus original monovalent COVID-19 doses only.
The researchers found that the effectiveness of a bivalent mRNA COVID-19 vaccine dose versus the original vaccine alone against COVID-19-related thromboembolic events was 47 and 51 percent among Medicare enrollees aged 65 years and older and among adults aged 18 years and older with end stage renal disease receiving dialysis, respectively. Among Medicare beneficiaries who were immunocompromised, VE was similar: 46 and 45 percent among adults aged 65 years and older and those aged 18 years and older with end-stage renal disease, respectively.
"To prevent COVID-19-related complications, including thromboembolic events, adults should stay up to date with recommended COVID-19 vaccination," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Further Support and Information on COVID-19
Read this next
Following Drop After COVID-19 Onset, Inappropriate Antibiotic Prescribing Is Up
WEDNESDAY, May 1, 2024 -- There was an initial decrease in inappropriate antibiotic prescriptions following onset of COVID-19, followed by an increase, according to a study...
Long-Term Smell, but Not Taste, Deficits Seen After COVID-19
WEDNESDAY, May 1, 2024 -- Olfactory dysfunction, especially for smell, is more common in individuals with prior COVID-19 versus individuals with no history of infection, with...
SARS-CoV-2 Vaccine Does Not Increase New-Onset Seizure Risk
TUESDAY, April 30, 2024 -- There is no risk for new-onset seizure incidence for individuals receiving a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine versus...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.